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Abstract
Background: Pathophysiological interactions between heart and lungs in heart failure (HF) are well recognized. We
investigated whether expression of different factors known to be increased in the myocardium and/or the circulation in HF
is also increased in alveolar macrophages in HF.
Methodology/Principal Findings: Lung function, hemodynamic parameters, gene expression in alveolar macrophages, and
plasma levels in the pulmonary and femoral arteries of HF patients (n=20) were compared to control subjects (n=16). Our
principal findings were: (1) Lung function was significantly lower in HF patients compared to controls (P,0.05). (2) mRNA
levels of ET-1, tumor necrosis factor (TNF)-a and interleukin-6 (IL-6) were increased in alveolar macrophages from HF
patients. (3) Plasma levels of ET-1, TNFa, IL-6 and MCP-1 were significantly increased in HF patients, whereas our data
indicate a net pulmonary release of MCP-1 into the circulation in HF.
Conclusions/Significance: Several important cytokines and ET-1 are induced in alveolar macrophages in human HF. Further
studies should clarify whether increased synthesis of these factors affects pulmonary remodeling and, directly or indirectly,
adversely affects the failing myocardium.
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Introduction
Chronic heart failure (HF) is an important and increasing cause
of cardiovascular morbidity and mortality. Despite the introduc-
tion of new therapeutic options, the five years mortality is above
50% [1], suggesting that important pathogenic mechanisms
remain unchallenged by current treatment modalities. In patients
with HF, the respiratory system has important clinical and
prognostic implications. Although pathophysiological interactions
between the heart and the lungs in HF are well recognized, most
attention has been drawn to the effects of impaired left ventricular
(LV) filling with increased filling pressure on pulmonary venous
circulation [2,3]. However, vasoactive peptides and cytokines
known to be synthesized in the heart in HF may directly or
indirectly affect the lungs and potentially also vice versa.
Activated alveolar macrophages synthesize numerous vasoac-
tive, mitogenic and inflammatory mediators [4], and these cells are
known to be important in various pulmonary disorders like
chronic obstructive pulmonary disease (COPD) and sarcoidosis
[5,6]. Previously, we have reported recruitment of macrophages
into the pulmonary alveoli as well as increased expression of
endothelin-1 (ET-1) [7], connective tissue growth factor (CTGF)
[8] and adrenomedullin [9] in alveolar macrophages in experi-
mental HF. Furthermore, previous investigations have suggested
that recruitment of monocytes from the bloodstream to the lungs
and alveoli is facilitated by cytokines, chemokines and vasoactive
peptides [4], and several of these mediators are known to be
induced in HF [10–12]. However, whether clinical HF is
associated with activation of alveolar macrophages is not clear.
Increased synthesis and release of vasoactive, mitogenic and
inflammatory mediators from alveolar macrophages in HF may
have a local effect contributing to pulmonary inflammation and
respiratory symptoms. Additionally, the release of these mediators
could potentially also, directly or indirectly, have effects on the
heart and the vessels. To further elucidate this issue, we in the
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chemokines and a vasoactive peptide known to be elevated within
the failing myocardium and in the circulation in HF in alveolar
macrophages from HF patients and healthy controls. We also
related the expression pattern of these mediators to clinical,
respiratory and hemodynamic characteristics of the HF patients.
Materials and Methods
Study Subjects
Twenty patients, age 53610 years, with stable symptomatic HF
for .3 months with NYHA class II-IV and LVEF ,50%
hospitalized at our hospital for evaluation of the etiology of HF or
assessing whether they were candidates for cardiac resynchroniza-
tion therapy or heart transplantation were consecutively included
in the study. Patients with infections within the last 4 weeks,
immunologic or connective tissue disease, and patients on anti-
inflammatory medications were excluded. Also patients with
spirometric values indicating COPD [forced expiratory volume
in 1 second (FEV1)/forced vital capacity (FVC) ,70%] were also
excluded. None of the patients had known pulmonary disorders.
Current or recent (within the last year before inclusion) smokers
were also excluded. Thirteen patients were prior smokers, and
eight of these patients had not been smoking for the last 15 years.
Patient characteristics are shown in Table 1. Sputum and venous
blood for RNA analysis (using PAXgene
TM Blood RNA Tubes,
PreAnalytiX, Hombrechtikon, Switzerland) were obtained from
all HF patients, whereas right heart catheterization with blood
sampling from the pulmonary artery and the femoral artery were
performed in 15 of the patients. Prior to sputum induction,
spirometry was performed using the Vmax system (Sensormedics,
Yorba Linda, CA, USA) and in accordance with the guidelines
recommended by the European Respiratory Society and Amer-
ican Thoracic Society [13]. Measurement of fractional eNO was
performed at flow rate to a constant 50 mL/sec (NIOX, Aerocrine
AB, Sweden). All patients were evaluated with echocardiography
according to the recommendations of the American Society of
Echocardiography [14]. Two control groups were included: 1)
Ten non-smoking patients, age 4768 years, undergoing right
heart catheterization for electrophysiological examination served
as controls for the plasma measurements in the pulmonary and
femoral arteries. All of these patients had supraventricular
arrhythmias but otherwise normal hemodynamic function without
signs or symptoms of myocardial dysfunction. 2) Sixteen healthy
non-smoking individuals, age 4667 years, served as controls for
examination of alveolar macrophages obtained from sputum and
mRNA levels in peripheral blood cells.
The investigation conforms to the principles outlined in the
Declaration of Helsinki. The study was approved by the regional
ethical committee (Regional Committee for Medical Research
Ethics South-East (REK Sør-Øst) and written informed consent
was received from all participants.
Right Heart Catheterization
Right heart catheterization was performed using a Swan-Ganz
pulmonary artery thermodilution catheter (Baxter Health Care
Corp., Santa Anna, CA, USA), and right atrial pressures,
pulmonary artery pressures, and pulmonary capillary wedge
pressure were measured. Cardiac output (CO) was recorded by
thermodilution as a mean of 3–5 measurements and cardiac index
calculated using CO divided by body surface area.
Induced Sputum and Isolation of Alveolar Macrophages
Alveolar macrophages were collected from induced sputum.
Three % (w/V), 4%, and 5% hypertonic saline were inhaled from
an ultrasonic nebuliser (DeVilbiss, Sunrise Medicals, Longmont,
CO, USA) during three 7-minute inhalation periods. At the end of
each inhalation period, expectorates were collected and subse-
quently processed as previously described [15]. Possible contam-
inating HLA-DR-positive lymphocytes in induced sputum were
removed using magnetic microbeads (Dynabeads Panmouse IgG;
Invitrogen, Oslo, Norway) coated with CD3 antibody (Diatec
Monoclonals AS, Oslo, Norway), before positive selection of
alveolar macrophages by use of magnetic microbeads (Dynabeads
Panmouse IgG; Invitrogen) coated with HLA-DR antibody
(Diatec) [16]. Differential cell count of the beads selection showed
a cell purity of 99% (median; range 96%–100%) macrophages,
with contamination of mainly squamous cells. In each step the
beads were incubated with the cells rotating for 10 minutes at 2–
8uC before positive cell collection. Differential cell counts (Diff-
Quik, Medion Diagnostics GmBH, Du ¨dingen, Germany) were
performed on a minimum of 300 cells by two blinded readers.
Table 1. Clinical and hemodynamic characteristics of the HF
population.
HF patients (n=20)
Age (year) 53610
Gender (male/female) 19/1
Etiology (CAD/DCM) 10/10
NYHA class (II/III/IV) (%) 37/54/9
History (%)
Diabetes mellitus 35
Hypertension 35
Previous myocardial infarction 50
Biochemical values
Creatinine (mmol/L) 111634
Nt-proBNP (pmol/L) 2976300
Hemodynamics
LVEF (%) 2969
PCWP (mmHg) 1366
Cardiac index (L?min
–1?m
–2) 2.360.7
MPAP (mmHg) 24611
PVR (dyne?s?cm
–5) 1916143
Medication (%)
ACE inhibitor 80
ARB 15
b-blocker 100
Diuretics 70
Aldosterone antagonist 55
Digitoxin 45
Statins 45
Warfarin 50
Data are presented as the mean 6 SD or number or percentage of subjects.
CAD, coronary artery disease; DCM, dilated cardiomyopathy; LVEF, left
ventricular ejection fraction; PCWP, pulmonary capillary wedge pressure; MPAP,
mean pulmonary artery pressure; PVR, pulmonary vascular resistance; ACE,
angiotensin converting enzyme; ARB, angiotensin II receptor blocker.
doi:10.1371/journal.pone.0036815.t001
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Alveolar macrophages were obtained by induced sputum from
healthy adult volunteers as described above. The cells (75610
3
cells/mL) were incubated in 96 well polystyrene TC-Treated
Microplate (200 mL/well; Corning, Schiphol-Rijk, Netherlands)
for 48 hours before stimulating with or without a toll-like receptor
(TLR)-4 agonist (LPS) from E. coli 026:B6 [100 ng/mL; Sigma, St
Louis, MO, USA]), a TLR2 agonist (Pam3Cys, 1 mg/mL; Sigma),
isoproterenol (20 mM; Sigma) and IL-1b (5 ng/mL; R&D
Systems, Minneapolis, MN, USA). After 5 hours and 24 hours,
cell-free supernatant was collected and stored at 280uC until use.
The cells were cultured in RPMI (E15-840) (PAA Laboratories
GmbH, Austria) with L-glutamine (2 mM) and added penicillin
(100 U/ml), streptomycin (100 mg/ml) and 10% (culture medium)
or 2.5% (stimulation medium) heat-inactivated fetal bovine serum
(A15-101) (PAA Laboratories GmbH).
Real-time Quantitative Reverse-transcription Polymerase
Chain Reaction (RT-PCR)
Total RNA was isolated from alveolar macrophages and the
PAXgene Blood RNA tubes and treated with DNaseI (PreAna-
lytiX). cDNA was synthesized using High Capacity RNA-to-
cDNA Master Mix (Applied Biosystems, Carlsbad, CA, USA).
Relative quantification of mRNA levels was performed by real-
time RT-PCR using 7500 Fast Real-Time PCR System (Applied
Biosystems). The relative standard curve method was used to
compute the relative gene expression data. The oligonucleotide
primers for PCR and the TaqMan probes were designed by the
use of PrimerExpress software (Applied Biosystems) using
sequences available from the GeneBank database (primer
sequences can be provided on request). 18S rRNA (TaqMan
rRNA control reagents, Applied Biosystems) was used for
normalization of target mRNA results. The data acquired were
analyzed with the Sequence Detector software (Applied Biosys-
tems).
Enzyme Immunoassay (EIA)
Concentrations of MCP-1 and ET-1 were measured by EIAs
obtained from R&D Systems. Concentrations of TNF-a and IL-6
were measured by ultrasensitive EIAs provided from Invitrogen
(Camarillo, CA, USA). The intra- and inter-assay coefficient of
variation were ,10% for all assays.
Statistical Analysis
All the data are presented as mean 6 SEM except for clinical
and hemodynamic characteristics which are presented as mean 6
SD. For comparisons of two groups, the Mann-Whitney U test was
used. For comparisons of more than 2 groups, the Kruskal-Wallis
test was used. If the Kruskal-Wallis test revealed significant
differences, subsequent pairwise analyses of individual group
means were performed with the Mann-Whitney U test. For
comparison of paired data, Wilcoxon’s signed-rank test was used.
The correlation analyses were assessed by Spearman rank
correlation test. Value of P,0.05 was considered to be statistically
significant. Linear regression analyses were used to investigate
whether cytokine and ET-1 levels were influenced by previous
smoking, adjusted for age and years since cessation of smoking.
Results
Lung Function, Diffusion Capacity, and Cellular Content
in Sputum
As shown in Table 2, lung function and diffusion capacity were
significantly reduced in HF patients (n=20) compared to controls
(n=16). There was no difference in exhaled nitric oxide (eNO)
levels between the two groups. Table 2 shows cell counts in
sputum. Although there was no significant difference in total cell
count per mg sputum, there was a trend toward increased cell
count in HF patients compared to healthy control subjects.
Gene Expression in Alveolar Macrophages and in
Peripheral Blood
As shown in Figure 1A, mRNA levels of ET-1, tumor necrosis
factor (TNF)-a and interleukin (IL)-6 were significantly increased
in alveolar macrophages from HF patients (n=20) relative to
controls (n=16), but not gene expression of IL-1b, monocyte
chemoattractant protein (MCP)-1, macrophage inflammatory
peptide (MIP)-1a and IL-18. In contrast, mRNA levels of the
mediators that were up-regulated in alveolar macrophages from
HF patients did not show any increased expression in peripheral
blood cells comparing HF patients and healthy controls
(Figure 1B). Moreover, HF patients had decreased MCP-1 mRNA
levels in peripheral blood as compared with healthy controls
(Figure 1B). Prior smoking did not influence the cytokine or ET-1
levels in alveolar macrophages in a linear regression model
adjusting for age and years since cessation of smoking.
Table 2. Lung function, exhaled NO value and differential
sputum cell count in the induced sputum population.
Control subjects HF patients
(n=16) (n=20)
FVC (L) 5.160.3 4.060.2*
FVC % predicted 112649 0 64*
FEV1 (L) 3.960.2 3.160.2*
FEV1% predicted 104638 7 64*
FEV1/FVC 77627 7 61
DLCO SI-units 10.860.6 7.260.5*
DLCO % predicted 101647 1 64*
FeNO (ppb) 21622 1 63
Total cell count/mg sputum 10396194 16396470
Neutrohpils/mg sputum 309662 8726316
Macrophages/mg sputum 7286144 7136176
Lymphocytes/mg sputum 160.4 361
Eosinophils/mg sputum 160.3 32621
% Neutrophils 33654 2 65
% Macrophages 67655 7 66
% Lymphocytes 060.0 060.0
% Eosinophils 060.0 160.3
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO,
diffusion capacity for carbon monoxide; eNO, exhaled nitric oxide; ppb, parts
per billion. Data are mean 6 SEM,
*p,0.05 versus controls.
doi:10.1371/journal.pone.0036815.t002
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in Alveolar Macrophages and Clinical and Hemodynamic
Parameters in HF Patients
When investigating the correlations between mRNA levels of
ET-1 and the cytokines that were up-regulated in alveolar
macrophages from HF patients (i.e., TNFa and IL-6) and clinical
and hemodynamic parameters in these patients, we found a strong
trend toward correlation between IL-6 mRNA levels and LV
function [LV ejection fraction (EF); r=20.53, p=0.06]. When
mRNA levels of the up-regulated mediators in alveolar macro-
phages from HF patients were separated into tertiles according to
LVEF, we found a significant up-regulation of ET-1, IL-6 and
MCP-1 in the tertile(s) with the lowest LVEF as compared with
healthy controls (Figure 1C). In addition, IL-6 were positively
correlated with the number of neutrophils in induced sputum
(r=0.87, p,0.001). There were no significant correlations
between mRNA levels of the up-regulated cytokines in alveolar
macrophages from HF patients and parameters of lung function
and diffusion capacity in these patients (data not shown).
Plasma Levels of Inflammatory Mediators in Pulmonary
and Femoral Artery
As shown in Figure 2A, plasma levels of ET-1, TNFa, IL-6 and
MCP-1 were markedly up-regulated in HF patients (n=15) as
compared with controls (n=10) in the femoral artery. Increased
plasma levels of ET-1 and a strong but not significant trend for
increased plasma levels of TNFa and IL-6 were also found in the
pulmonary artery. While there was no transpulmonary gradient
for ET-1, TNFa and IL-6 in either HF or control patients, MCP-1
levels were higher in pulmonary as compared with femoral artery
only in the controls, suggesting a net release of MCP-1 from the
lungs during HF (p,0.05 when comparing transpulmonary
gradients).
Stimulation of Alveolar Macrophages
To elucidate the possible mechanisms for the up-regulated
cytokines in alveolar macrophages from HF patients, we finally
exposed alveolar macrophages from healthy controls to different
stimuli with relevance to HF. As shown in Figure 2B, the TLR2
agonist Pam3Cys induced a significant increase in the release of
IL-6 and TNFa from alveolar macrophages, whereas the TLR4
agonist lipopolysaccharide (LPS) induced a significant increase in
the release of IL-6. In contrast to these rather modest effects, the
b-receptor agonist isoproterenol and IL-1b induced a marked
increase in the release of ET-1 (Figure 2B). None of the stimuli had
any effects on MCP-1 release (data not shown).
Discussion
In the present study, we show that patients with chronic HF
have enhanced expression of several inflammatory and vasoactive
mediators (i.e., ET-1, TNFa and IL-6) in alveolar macrophages as
compared with healthy controls. Our findings suggest that chronic
HF is accompanied by pulmonary inflammation involving
activation of alveolar macrophages, potentially representing an
inflammatory interaction between the lungs and the myocardium
during HF.
It is well known that HF and COPD frequently coexist [17,18].
In a recent study, the prevalence of COPD in a HF population,
consisting of ,70% previous or current smokers, was 35% based
on spirometry-defined criteria [19]. In the current study of non-
Figure 1. Gene expression in alveolar macrophages and in peripheral blood. A. mRNA levels of ET-1, TNFa, IL-1b, MCP-1, MIP-1a and IL-18
in alveolar macrophages in HF patients (n=20) and controls (CTR, n=16). B. Gene expression of the same mediators in peripheral blood cells. Gene
expression was assessed by real-time quantitative RT-PCR in relation to the control gene18S rRNA. C. mRNA levels of ET-1, TNFa, IL-6 and MCP-1 in
alveolar macrophages from HF patients (n=20) and controls (CTR, n=16) where mRNA levels in HF patients are separated into tertiles (T) according
to left ventricular ejection fraction (LVEF) (T1, LVEF 34–47%; T2, 27–34%; T3, 20–25%). Gene expression was assessed by real-time quantitative RT-PCR
in relation to the control gene18S rRNA. Data are mean6SEM. *p,0.05 and **p,0.01 versus controls.
doi:10.1371/journal.pone.0036815.g001
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diffusion capacity in HF patients as compared with healthy
controls. Additionally, HF patients showed enhanced gene
expression of ET-1, IL-6 and TNFa in alveolar macrophages as
compared with healthy controls. A similar increase in mRNA
levels was not found in peripheral blood, indicating that the
increase in gene expression is primarily taking place in the lungs
and is not a result of induction in monocytes in the circulation
before entering the pulmonary compartment. We have previously
shown enhanced expression of adrenomedullin in alveolar
macrophages from HF patients [9], and our findings in the
present study suggest that the activation of these cells during HF
includes increased expression of several mediators with relation to
HF.
Pulmonary remodeling is a well recognized consequence of
chronic HF [20], but the mechanisms involved in this process are
unclear. Previously, we reported enhanced pulmonary expression
of CTGF and ET-1 in experimental HF, with enhanced
expression in alveolar macrophages [7,8], potentially contributing
to pulmonary fibrosis and remodeling. In the present study, we
show enhanced expression of ET-1 as well as several inflammatory
cytokines in alveolar macrophages in clinical HF. In addition, IL-6
was correlated with the number of neutrophils in induced sputum.
Based on the ability of these mediators to promote inflammation
and vascular smooth muscle cell activation, it is tempting to
hypothesize that the enhanced expression of these mediators could
contribute to inflammation and pulmonary remodeling during
HF. Moreover, HF patients had increased plasma levels of TNFa,
IL-6 and ET-1 in both pulmonary and femoral artery as compared
with controls, which indicate that both the lungs and the
myocardium could be exposed to these mediators. However,
although the lack of transpulmonary gradients, representing the
net result of trapping and release of these mediators during
pulmonary and myocardial circulation, does not exclude an
inflammatory interaction between the lungs and myocardium in
HF, the hypothesis that this inflammatory loop could contribute to
remodeling in both organs will have to be examined in
forthcoming studies.
The reason for the enhanced expression of several inflammatory
mediators in alveolar macrophages during HF is at present not
clear, but could involve mechanisms such as pulmonary vascular
congestion and shear stress secondary to chronic HF. Also, it is
well known that pulmonary bacterial infections could induce
exacerbation of cardiovascular disease [21]. This phenomenon
could potentially involve TLR-mediated activation of alveolar
macrophages, and in the present study we show that TLR2 and
TLR4 activation induce IL-6 and TNFa release in these cells.
Moreover, ET-1 is a potent inflammatory and vasoactive cytokine
that has been suggested to participate in the pathogenesis of
myocardial failure and pulmonary remodeling during HF [22,23].
Here, we show that IL-1b, representing an upstream inflammatory
mediator in innate immune responses, and b-adrenergic receptor
activation profoundly induce the release of ET-1 from alveolar
macrophages. ET-1 has been shown to induce IL-1b production
[24], and if such interactions are operating in alveolar macro-
phages, it could represent an inflammatory loop that is operating
in the lungs during HF.
In conclusion, we found that several important cytokines are
induced in alveolar macrophages in human HF. However,
relatively few patients were examined and the potential pathogenic
importance of alveolar macrophage-mediated inflammation in HF
is at present unclear. Further studies should clarify whether this
induction affects pulmonary remodeling and whether the in-
creased synthesis of these factors, directly or indirectly, may
adversely affect the failing myocardium.
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